Venclexta (venetoclax) — Medica
Myelodysplastic Syndrome
Initial criteria
- age ≥ 18 years
- EITHER chronic myelomonocytic leukemia-2 OR higher-risk disease (IPSS-R intermediate-, high-, or very-high risk)
- used in combination with azacitidine OR decitabine
Approval duration
1 year